Published by Peptide Protocols · Reviewed September 2026 · How we make these pages · Educational & research purposes only — not medical advice.
Most weight-research conversations center on GLP-1 compounds like semaglutide and tirzepatide. Cagrilintide comes at appetite from a different hormone entirely — and its combination with semaglutide, nicknamed CagriSema, is one of the most-watched investigational stories of 2026.
Cagrilintide is a long-acting amylin analog. Amylin is a hormone released alongside insulin that signals fullness and slows how fast the stomach empties. A long-acting version is studied for the same broad goal as the GLP-1 class — appetite and body-weight research — but through the amylin pathway rather than the GLP-1 pathway.
CagriSema pairs cagrilintide (amylin) + semaglutide (GLP-1) in one investigational combination. The idea researchers explore is whether hitting two complementary fullness pathways at once does more than either alone. It's a combination product still working through the clinical process — not an approved medication.
If you want the two-way comparison first, start with tirzepatide vs semaglutide, then retatrutide for the triple-pathway story.
And the class-wide catch applies here too: any compound that meaningfully lowers appetite can take lean muscle along with fat if you don't defend it with protein and resistance training. That's the single most important thing to plan for.
Vial mg + bacteriostatic water mL + your target mcg → mL and U-100 syringe units, instantly. Free, no sign-up, 60+ research peptides preset — plus dedicated calculators and BAC-water charts for BPC-157, retatrutide, tirzepatide, semaglutide, tesamorelin and CJC-1295/ipamorelin.
Open the free peptide calculator →Research & educational use only — never medical advice.
We do not recommend or partner with any peptide supplier. Use the checklist instead: third-party COAs that match your batch and lot, stated purity, clear research-use labeling, real support and proper cold-chain shipping.
The supplier checklist →Educational content only. Confirm the legal status where you live before ordering anything.
No — it's an amylin analog. It works on the amylin fullness pathway rather than the GLP-1 pathway, which is what makes CagriSema (cagrilintide + semaglutide) a two-pathway combination.
As of 2026 it's investigational — still in the clinical process, not an approved medication. See our FDA status guide for the broader picture.
Any strong appetite-lowering compound can. Protein and resistance training are the levers that protect muscle — see the Muscle-Preservation guide.
The GLP-1 Muscle-Preservation guide applies to any appetite-lowering compound in this family — protein targets, low-appetite eating, and an Excel tracker.
Browse the shop on Etsy →The one formula, a BAC-water chart, and the 10 most-researched beginner peptides — the math done for you. Print it for the fridge.
🎁 Send me the free cheat sheet →